M&A Deal Summary

Daiichi Sankyo Acquires Ranbaxy Laboratories

On June 11, 2008, Daiichi Sankyo acquired life science company Ranbaxy Laboratories for 5.5B USD

Acquisition Highlights
  • This is Daiichi Sankyo’s 2nd transaction in the Life Science sector.
  • This is Daiichi Sankyo’s largest (disclosed) transaction.
  • This is Daiichi Sankyo’s 1st transaction in India.
Investment Fate
  • Ranbaxy Laboratories was divested to a consortium of strategic buyers in 2014 for 4.0B USD.

M&A Deal Summary

Date 2008-06-11
Target Ranbaxy Laboratories
Sector Life Science
Buyer(s) Daiichi Sankyo
Deal Type Add-on Acquisition
Deal Value 5.5B USD

Target

Ranbaxy Laboratories

New Delhi, India
website
Ranbaxy Limited is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. Ranbaxy’s continued focus on R&D has resulted in several approvals in developed and emerging 4 markets, many of which incorporate proprietary Novel Drug Delivery Systems and technologies developed at its own labs.

Search 177,782 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Daiichi Sankyo

Tokyo, Japan

website


Category Company
Founded 1899
Sector Life Science
Employees16,033
Revenue 962.5B JPY (2021)
DESCRIPTION

Daiichi Sankyo established through merger of Sankyo and Daiichi pharmaceutical. The Group manufactures pharmaceuticals for human/veterinary use and medical tools and equipment. It also researches and promotes products through related companies throughout the world. The Group also produces food, food additives, livestock feeds, and agrochemicals. Daiichi Sankyo was incorporated in 1899 and is based in Tokyo, Japan.


DEAL STATS #
Overall 2 of 4
Sector (Life Science) 2 of 4
Type (Add-on Acquisition) 2 of 4
Country (India) 1 of 1
Year (2008) 2 of 2
Size (of disclosed) 1 of 4
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2008-05-21 U3 Pharma AG

Martinsried, Germany

U3 Pharma AG was advancing a portfolio of novel antibody-based therapeutics to be used as mono therapies and combination therapies for the treatment of cancer. The two lead antibodies were potential therapies for breast, lung and colorectal cancers, among others

Buy $234M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2011-02-28 Plexxikon

Berkeley, California, United States

Plexxikon is a leader in the discovery and development of novel, small molecule pharmaceuticals. With its Scaffold-Based Drug Discovery Platform™, Plexxikon uses compound and target structural data to guide chemistry early in the drug lead generation process within various families of drug targets. The Company has clinical and preclinical stage programs in several therapeutic areas, including metabolic disease, oncology, inflammation, CNS and cardiovascular disease.

Buy $805M